VP, Regulatory Affairs
Pharnext
20+ years experience in the pharmaceutical industry with a focus on Regulatory Affairs Strategy Development, Project Management, and Pharmaceutical Development.
Successfully developed and implemented regulatory strategies leading to pre-IND/developmental activities (EOP2/pre NDA), CMC technical writing, FDA meetings (Type A, B and C), global eCTD NDA/MAA submissions, lifecycle post-approval submissions, and late-stage labeling discussions.
Experience across various Divisions of FDA including Anti-infectives, Neurology, Urology/Reproductive Health, Metabolism, Gastroenterology, Oncology, CBER (Gene Therapy), and Orphan Products Development.
Currently heading RA at Pharnext SA since 2021.
Disclosure information not submitted.
Wednesday, October 4, 2023
10:45 AM – 11:15 AM EDT
Is Animal Testing Really No Longer Needed for Drug Development?
Thursday, October 5, 2023
3:30 PM – 4:30 PM EDT